Respiratory syncytial virus immune globulin intravenous: Indications for use

N. A. Halsey, J. S. Abramson, P. J. Chesney, M. C. Fisher, M. A. Gerber, D. S. Gromisch, S. Kohl, S. M. Marcy, Dennis L Murray, G. D. Overturf, R. J. Whitley, R. Yogev, G. Peter, C. B. Hall, Jr Overall, R. Berkelman, W. A. Orenstein, R. Breiman, M. C. Hardegree, R. F. JacobsN. E. MacDonald, N. R. Rabinovich, W. Oh, L. R. Blackmon, A. A. Fanaroff, B. V. Kirkpatrick, H. M. MacDonald, C. A. Miller, A. Papile, C. T. Shoemaker, M. E. Speer, P. Johnson, Jr Greene, D. D. McMillan, D. Rowley, L. L. Wright, J. C. Langer

Research output: Contribution to journalReview article

79 Scopus citations

Abstract

Respiratory syncytial virus immune globulin intravenous (RSV-IGIV) has been approved by the Food and Drug Administration for use in the prevention of severe RSV infections in infants and children younger than 24 months with bronchopulmonary dysplasia or a history of premature birth (≤35 weeks of gestation). RSV-IGIV administered monthly during the RSV season resulted in a 41% to 65% reduction in hospitalization rates in two clinical trials; however, RSV-IGIV is costly, and intravenous administration can be logistically demanding. RSV-IGIV should be considered for infants with bronchopulmonary dysplasia who are receiving or have received oxygen therapy in the past 6 months. Infants with gestational ages of 32 weeks or less may also benefit clinically from RSV-IGIV prophylaxis. Immunization with measles- containing vaccines should be delayed for 9 months after the last dose of RSV-IGIV, but no changes need to be made for all other routinely administered vaccines. RSV-IGIV has not been approved for use in children with congenital heart disease, and available data indicate that RSV-IGIV should not be administered to children with cyanotic congenital heart disease because of safety concerns.

Original languageEnglish (US)
Pages (from-to)645-650
Number of pages6
JournalPediatrics
Volume99
Issue number4
StatePublished - Apr 1 1997

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'Respiratory syncytial virus immune globulin intravenous: Indications for use'. Together they form a unique fingerprint.

  • Cite this

    Halsey, N. A., Abramson, J. S., Chesney, P. J., Fisher, M. C., Gerber, M. A., Gromisch, D. S., Kohl, S., Marcy, S. M., Murray, D. L., Overturf, G. D., Whitley, R. J., Yogev, R., Peter, G., Hall, C. B., Overall, J., Berkelman, R., Orenstein, W. A., Breiman, R., Hardegree, M. C., ... Langer, J. C. (1997). Respiratory syncytial virus immune globulin intravenous: Indications for use. Pediatrics, 99(4), 645-650.